wherea
mani
larg
pharma
cso
medic
biolog
background
phd
chemistri
give
differ
perspect
drug
develop
cso
peer
ye
train
chemistri
phd
level
postdoc
georg
whitesid
harvard
appli
enzymolog
bit
mixtur
biolog
chemistri
work
molecular
biolog
genentech
gilead
start
research
took
respons
preclin
develop
deal
everyth
pharmacolog
vitro
metabol
adm
absorpt
distribut
metabol
excret
toxicolog
took
develop
side
thing
gilead
sinc
spent
time
work
develop
issu
use
chemist
long
time
ago
actual
work
everyth
except
product
price
commerci
gilead
one
secret
top
level
realli
seek
understand
whole
spectrum
drug
develop
sometim
see
peopl
work
eleg
biolog
problem
order
make
product
get
biolog
right
get
chemistri
right
well
sometim
look
molecul
say
hopeless
anoth
thing
think
often
underappreci
manufactur
side
chemistri
learn
lot
tamiflu
oseltamivir
start
materi
synthesi
extrem
expens
look
start
materi
led
us
chines
spice
star
anis
took
us
lot
work
get
ultim
look
product
give
patient
insur
compani
reimburs
make
appropri
cost
alway
think
product
hurdl
overcom
make
product
good
seen
whole
drug
discoveri
spectrum
lead
optim
clinic
trial
approv
label
commerci
reimburs
look
time
gilead
brought
product
market
antivir
next
antivir
r
hepat
c
start
done
realli
noth
left
develop
singl
pill
administ
daili
well
toler
lead
cure
rate
within
week
treatment
stop
hepat
c
research
around
year
ago
also
made
huge
progress
hiv
develop
small
safe
welltoler
pill
respons
rate
year
realli
optim
hiv
drug
point
much
left
treatmentna
patient
still
work
longact
inject
patient
might
prefer
still
work
oncedaili
pill
highli
treatmentexperienc
patient
develop
resist
drug
lot
work
mainten
therapi
done
next
big
step
cure
hiv
still
chronic
viral
diseas
ca
nt
fulli
clear
big
question
elicit
immun
system
clear
viru
call
kickandkil
approach
challeng
hiv
infect
viru
hide
nonrepl
cell
kick
cell
wake
speak
viru
start
reproduc
kill
cell
subject
well
control
antivir
viru
ca
nt
go
anywher
look
use
agonist
deliv
kick
broadli
neutral
antibodi
help
control
awaken
viru
monkey
model
hiv
show
combin
actual
cure
monkey
immunodefici
viru
infect
excit
stuff
cours
whether
work
human
remain
seen
us
chanc
success
reason
certainli
worth
spend
money
best
chanc
success
probabl
deliv
combin
earli
infect
viral
divers
minim
tri
kick
kill
someon
infect
year
mani
quasispeci
hiv
broadli
neutral
antibodi
enough
control
everyth
quick
word
hepat
b
realli
good
drug
patient
take
long
term
suppress
viru
chronic
viral
diseas
spontan
clear
low
percentag
patient
could
increas
would
huge
contribut
health
system
one
programm
ebola
cours
commerci
opportun
ebola
nearli
disappear
difficult
studi
anoth
thing
work
preclin
broad
spectrum
antirespiratori
viru
programm
flu
paraflu
respiratori
syncyti
viru
coronaviru
rhinoviru
caus
similar
symptom
even
though
virolog
complet
differ
one
anoth
could
come
someth
broadspectrum
activ
least
could
use
virus
encod
polymeras
larg
librari
polymeraseinhibit
nucleosid
made
hepat
c
programm
look
expand
librari
test
somewhat
broader
spectrum
activ
would
compar
scope
viral
programm
versu
opportun
gilead
start
unless
new
viru
show
viral
space
somewhat
limit
start
work
area
still
million
peopl
hepat
c
market
disappear
clearli
shrink
good
thing
hiv
hepat
b
still
chronic
viral
diseas
barrier
entri
new
drug
gone
way
alreadi
realli
safe
effect
therapi
ye
unless
new
viru
show
viral
space
somewhat
limit
start
work
area
driven
gilead
grow
interest
oncolog
us
billion
acquisit
kite
pharma
last
year
becom
bigger
compani
market
capit
wall
street
becom
concern
growth
next
us
clearli
oncolog
big
growth
area
went
look
oncolog
opportun
great
detail
look
immunooncolog
decid
extrem
competit
space
nt
realli
anyth
offer
look
target
therapi
nt
realli
find
anyth
scientif
interest
enough
reason
term
commerci
price
decid
cell
therapi
data
novarti
kite
gener
realli
incred
think
chimer
antigen
receptor
car
cell
potenti
expand
b
cell
malign
earlier
line
therapi
ultim
even
solid
tumour
think
could
make
realli
big
differ
current
one
focus
mention
earlier
manufactur
underappreci
drug
develop
car
manufactur
particularli
challeng
especi
firstgener
autolog
therapi
need
tailor
patient
think
potenti
allogen
car
ts
competit
contend
space
includ
recent
launch
allogen
therapeut
clearli
futur
autolog
car
ts
go
requir
increas
effici
manufactur
mayb
local
manufactur
site
anoth
approach
cours
work
allogen
cell
conceptu
fairli
straightforward
simpli
knock
major
histocompat
complex
human
leukocyt
antigen
hla
donor
cell
collabor
sangamo
therapeut
zincfing
nucleas
allogen
car
ts
bring
challeng
well
one
thing
nt
hla
surfac
cell
immun
system
recogn
cell
nonself
destroy
probabl
go
see
less
persist
car
cell
still
lot
work
first
gener
car
current
price
nearli
draw
afford
concern
launch
hcv
drug
cost
per
cours
treatment
thought
current
cost
drug
true
limelight
unfortun
hepat
c
drug
talk
privat
insur
compani
nt
think
problem
price
total
cost
altern
interferon
plu
ribavirin
estim
problem
volum
mani
patient
immedi
want
go
treatment
nt
money
system
pay
price
hepat
c
therapi
fraction
use
realli
gone
away
moment
nt
heard
critic
price
car
ts
car
ts
far
use
rel
small
patient
popul
altern
death
realli
lifesav
therapi
becom
broadli
use
move
earlier
line
therapi
current
price
one
system
afford
look
oncolog
drug
benefit
month
surviv
cost
think
realli
need
debat
societi
whether
price
right
know
though
opinion
hepat
c
treatment
cost
effect
great
therapi
provid
cure
elimin
comorbid
also
true
hiv
drug
look
oncolog
drug
benefit
month
surviv
cost
think
realli
need
debat
societi
whether
price
right
interview
bischofberg
left
gilead
becom
ceo
cancer
biotech
krono
bio
